Gelteq Limited Ordinary Shares·Healthcare

2025 Non-GAAP Net Income Totaled $162,000 or $0.02 Per Share Record Results Driven by Fifth Sequential Quarter of Record-Setting Revenues, with the Momentum Setting Stage for Another Year of Double-Digit Growth LAS VEGAS, NV / ACCESS Newswire / April 8, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported audited results for the year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026 LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

Gelteq Limited (NASDAQ: GELS - Get Free Report) shares were down 3.2% during trading on Tuesday. The stock traded as low as $0.73 and last traded at $0.7496. 3,215 shares were traded during trading, a decline of 84% from the average daily volume of 19,565 shares. The stock had previously closed at $0.7741. Analysts Set

MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) and Healthy Extracts™ Inc. (“Healthy Extracts”) today announced the signing of a Memorandum of Understanding (“MoU”) formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution.

Shares of Gelteq Ltd. jumped 69.25% in after-hours trading following the company's announcement of encouraging preclinical data for its cannabinoid oral gel platform.

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients.
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Healthcare
Drug Manufacturers - Specialty & Generic
7
2024-10-29
0.04